Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Surufatinib Improves PFS in Advanced Pancreatic NETs
September 20th 2020The novel VEGFR, FGFR, and CSF-1R inhibitor surufatinib yielded a statistically significant and clinically meaningful progression-free survival benefit compared with placebo in patients with advanced pancreatic neuroendocrine tumors.
Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast Cancer
September 20th 2020Stephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.
Regorafenib Showed Modest Activity in Ewing Sarcoma
Regorafenib extended progression-free survival at 24 weeks compared with placebo for patients with Ewing sarcoma in the phase 2 REGOBONE study. However, the oral multi-kinase inhibitor failed to meet the study’s primary endpoint of non-progression at 8 weeks.
Updated Findings Show Olaparib Prolongs OS in Men with mCRPC
September 20th 2020Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.
EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC
September 20th 2020The combination of amivantamab and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib-resistant patients with advanced EGFR-mutant non–small cell lung cancer.
First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC
September 20th 2020Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.
DART Molecule MGD019 Displays Monotherapy Efficacy in Heavily Pretreated Solid Tumors
September 20th 2020An acceptable safety profile coupled with pharmacokinetic and pharmacodynamic data for the DART molecule MGD019 were reported during the European Society for Medical Oncology Virtual Congress 2020 from results of a first-in-human study.
Overall survival benefits of frontline maintenance treatment with avelumab in patients with advanced urothelial cancer were found to be positively associated with biomarkers of immune activity and negativity linked with biomarkers of tumor homeostasis and chronic inflammation.
QoL Maintained in Patients With Gynecologic Malignancies Treated on PRIMA Trial
September 20th 2020Quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Abemaciclib Reduces the Risk of Recurrence in High-Risk Early Breast Cancer
September 20th 2020The addition of abemaciclib to endocrine therapy led to a significant reduction in the risk of invasive disease versus endocrine therapy alone in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.
PORT Not Recommended as Standard of Care in Completely Resected Stage IIIAN2 NSCLC
September 20th 2020Post-operative radiotherapy was linked with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non–small cell lung cancer and thus cannot be recommended as a standard of care for this population.
Atezolizumab Plus Chemo Significantly Improves pCR Rates in Early TNBC, Irrespective of PD-L1 Status
September 20th 2020The addition of neoadjuvant atezolizumab to nab-paclitaxel plus doxorubicin and cyclophosphamide significantly improved pathologic complete responses in patients with stage 2 or stage 3 triple-negative breast cancer, compared with placebo plus chemotherapy.
Sacituzumab Govitecan Significantly Improves Survival in Metastatic TNBC
Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.
Sacituzumab Govitecan Shows Sustained Activity in Heavily Pretreated Metastatic Urothelial Carcinoma
Sacituzumab govitecan-hziy continued to showcase significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.
Updated Data Demonstrate Continued PFS and OS Benefit With Ripretinib in Advanced GIST
September 19th 2020The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.
SOLAR-1 OS Data Suggests Benefit in HR+/HER2– PIK3CA-Mutant Breast Cancer Subgroups
September 19th 2020Although the SOLAR-1 trial did not cross the prespecified O’Brien-Fleming efficacy boundary in postmenopausal patients with PIK3CA-mutant, hormone receptor–positive, HER2-negative advanced breast cancer, alpelisib and fulvestrant nevertheless prolonged the median OS.
Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC
September 19th 2020The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.
.jpg?fit=crop&auto=format)
